Investigators in the phase 3 BENEFIT study evaluated MRD negativity at 12 and 24 months in patients with newly diagnosed multiple myeloma (NDMM) transplant-ineligible (TI) patients.

A recent study shows a regimen of low-dose homoharringtonine, cytarabine, and G-CSF (HAG) is an effective and promising treatment for pediatric patients with AML.

The phase 3, open-label, single arm BOND-003 trial also evaluated cretostimogene in cohort P with papillary-only high-grade NMIBC who failed prior BCG therapy.

Trastuzumab deruxtecan continues to demonstrate superior safety and efficacy compared with trastuzumab emtansine in patients with high-risk, HER2-positive early breast cancer who have residual ...

Investigators evaluated atezolizumab combined with bevacizumab and non–platinum-based chemotherapy for patients with recurrent ovarian cancer.

Medicare and Medicaid dual eligibility, higher comorbidity burden, and preexisting anxiety independently tied to greater risk.

The current study assesses whether the MNW could address global disparities in oncology education by reaching low- and middle-income countries and if it was able to advance gender inclusivity in ...

Researchers developed and validated a machine-learning algorithm for predicting nutritional risk in patients with nasopharyngeal carcinoma.

Researchers compared the safety and efficacy of BrECADD vs eBEACOPP, a standard regimen, in the newly diagnosed, advanced-stage classical HL setting.

HealthDay News — Among adults aged 45 to 49 years who are newly eligible for colorectal cancer (CRC) screening, there are no significant differences in screening uptake in adjusted analyses, according ...

In this retrospective study, researchers aimed to characterize persistent toxicities experienced by patients with TNBC who were treated with pembrolizumab in the curative setting.

A nurse-led intervention addressed completion of preinfusion lab tests, improving patient preparedness for infusion, multidisciplinary coordination, and patient outcomes.